View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBiocept 향후 성장Future 기준 점검 2/6Biocept은 연간 수입과 매출이 각각 56.6%와 67.1% 증가할 것으로 예상되고 EPS는 연간 77.3%만큼 증가할 것으로 예상됩니다.핵심 정보56.6%이익 성장률77.26%EPS 성장률Biotechs 이익 성장23.4%매출 성장률67.1%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트21 Sep 2023최근 향후 성장 업데이트Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.Breakeven Date Change • Apr 18No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.Breakeven Date Change • Feb 14Forecast to breakeven in 2025The 2 analysts covering Biocept expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$5.04m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.Major Estimate Revision • May 19Consensus revenue estimates increase to US$37.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$28.4m to US$37.5m. Forecast losses expected to reduce from -US$1.17 to -US$0.82 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$12.00 unchanged from last update. Share price was steady at US$4.59 over the past week.Price Target Changed • May 09Price target decreased to US$12.00Down from US$20.30, the current price target is provided by 1 analyst. New target price is 161% above last closing price of US$4.61. Stock is up 12% over the past year.분석 기사 • Dec 22Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?With the business potentially at an important milestone, we thought we'd take a closer look at Biocept, Inc.'s...모든 업데이트 보기Recent updates공지 • Oct 26Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite IndexBiocept, Inc. will be removed from NASDAQ Composite Index.공지 • Oct 21Biocept's Securities To Be Delisted from NasdaqOn October 16, 2023, Biocept, Inc. received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined that the Company’s securities will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, in connection with the filing of a voluntary case under Chapter 7 of Title 11 of the United States Bankruptcy Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 2023. Pursuant to the Delisting Notice, Nasdaq’s decision was based on the following factors: (i) The public interest concerns raised by the filing; (ii) concerns regarding the residual equity interest of the existing listed securities holders; and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, on May 17, 2023, Staff also notified the Company that it failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing pursuant to Listing Rule 5550(b)(1), which deficiency serves as an additional and separate basis for delisting. The Staff letter indicates that the trading of the Company’s common stock and warrants will be suspended at the opening of business on October 25, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to appeal the determination and, therefore, it is expected that its Common Stock will be delisted, which would not affect any actions it may take in bankruptcy. Trading of the Common Stock will be suspended by Nasdaq at the opening of business on October 25, 2023.공지 • Oct 19Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI IndexBiocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index공지 • Sep 22Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung CancerBiocept, Inc. announced the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. The FORESEE trial is specifically designed to measure the impact of CNSide on physicians' clinical decisions to generate the data needed to help reach this goal. FORESEE is a two-part prospective clinical trial designed to follow subjects and collect data from each enrollee at four key time points in their treatment, as well as to compare CNSide cell detection in the cerebrospinal fluid to that of conventional cytology. CNSide has notable advantages over current standards of care, such as cytology, clinical evaluation and MRI, which have limited sensitivity and specificity. Biocept expects to have results from the feasibility phase of the FORESEE trial in the first half of 2024 and to then begin enrolling between 40 and 100 subjects in the trial's validation phase. Enrollment is currently open at four clinical sites with two additional sites expected to join the FORESEE trial in The near term.New Risk • Aug 17New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: US$1.4m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$19m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (327% increase in shares outstanding). Market cap is less than US$10m (US$2.24m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.6m net loss in 3 years). Revenue is less than US$5m (US$1.4m revenue).Reported Earnings • Aug 16Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)Second quarter 2023 results: US$3.50 loss per share (improved from US$16.83 loss in 2Q 2022). Net loss: US$3.63m (loss narrowed 62% from 2Q 2022). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.공지 • Jun 21+ 1 more updateBiocept, Inc. Announces Executive ChangesBiocept, Inc. has named Antonino Morales as President effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer, and Director. Mr. Morales has served as a member of Biocept's Board since July 2021 and was a member of the Audit Committee from August 2021 until his appointment as interim Chief Financial Officer. He has more than 30 years of broad executive leadership experience and has served in executive management or consulting roles with various Fortune 100 companies, including Citibank, Bank of America, Arthur Andersen, Mazda North America and McDonald's. Mr. Morales has also led multiple private equity-backed startup companies. He received a Bachelor of Science in Finance from the University of Southern California and is a licensed CPA.공지 • May 16Biocept Expects to Receive Non-Compliance Notice Form NasdaqAs reported in Biocept, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on May 10, 2023, the Company's stockholders' equity as of March 31, 2023 was $2.4 million. As a result, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirements set in Nasdaq Stock Market Rule 5550(b) (the Rule"). The Company expects to receive a formal notice (the Notice") from The Nasdaq Stock Market LLC (Nasdaq") on or about May 15, 2023 to formally notify the Company of non-compliance with the Rule. The Company discussed the noncompliance with the Rule with Nasdaq on May 12, 2023. Pursuant to the Notice and Nasdaq rules, the Company will have 45 calendar days after receipt of the Notice to submit a plan to regain compliance with the Rule. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to provide evidence of compliance. There can be no assurance that the Company will be able to regain compliance with the Rule.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.Breakeven Date Change • Apr 18No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.분석 기사 • Apr 17Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For GrowthThose holding Biocept, Inc. ( NASDAQ:BIOC ) shares would be relieved that the share price has rebounded 48% in the last...Breakeven Date Change • Feb 14Forecast to breakeven in 2025The 2 analysts covering Biocept expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$5.04m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$2.16, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 79% over the past three years.Reported Earnings • Feb 17Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2021 results: US$0.041 loss per share (up from US$0.37 loss in 3Q 2020). Revenue: US$17.5m (up 165% from 3Q 2020). Net loss: US$624.7k (loss narrowed 87% from 3Q 2020). Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 37% compared to a 187% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$3.95, the stock trades at a trailing P/E ratio of 21.5x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 65% over the past three years.분석 기사 • Nov 23Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True PositionEven though Biocept, Inc. ( NASDAQ:BIOC ) posted strong earnings recently, the stock hasn't reacted in a large way. We...Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$34.9m (up 431% from 3Q 2020). Net income: US$854.1k (up US$5.73m from 3Q 2020). Profit margin: 2.4% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.분석 기사 • Aug 19Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) EarningsCelebrations may be in order for Biocept, Inc. ( NASDAQ:BIOC ) shareholders, with the covering analyst delivering a...Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$12.0m (up US$11.1m from 2Q 2020). Net loss: US$1.83m (loss narrowed 72% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.분석 기사 • Jul 03Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time BeingIn the past three years, the share price of Biocept, Inc. ( NASDAQ:BIOC ) has struggled to grow and now shareholders...Major Estimate Revision • May 19Consensus revenue estimates increase to US$37.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$28.4m to US$37.5m. Forecast losses expected to reduce from -US$1.17 to -US$0.82 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$12.00 unchanged from last update. Share price was steady at US$4.59 over the past week.Reported Earnings • May 13First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$17.8m (up US$16.3m from 1Q 2020). Net income: US$2.60m (up US$10.9m from 1Q 2020). Profit margin: 15% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Price Target Changed • May 09Price target decreased to US$12.00Down from US$20.30, the current price target is provided by 1 analyst. New target price is 161% above last closing price of US$4.61. Stock is up 12% over the past year.Reported Earnings • Mar 31Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$27.5m (up 397% from FY 2019). Net loss: US$17.8m (loss narrowed 30% from FY 2019). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.분석 기사 • Mar 13Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price GainBiocept, Inc. ( NASDAQ:BIOC ) shareholders might be concerned after seeing the share price drop 19% in the last month...Is New 90 Day High Low • Feb 05New 90-day high: US$6.70The company is up 51% from its price of US$4.45 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.분석 기사 • Jan 26We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, Biocept ( NASDAQ:BIOC ) stock...Is New 90 Day High Low • Jan 20New 90-day high: US$6.23The company is up 38% from its price of US$4.52 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.분석 기사 • Dec 22Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?With the business potentially at an important milestone, we thought we'd take a closer look at Biocept, Inc.'s...Reported Earnings • Nov 20Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$6.59m (up 331% from 3Q 2019). Net loss: US$4.88m (loss narrowed 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 71% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Nov 20Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 163%. Earnings per share (EPS) missed analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 154%, compared to a 365% growth forecast for the Biotechs industry in the US.Reported Earnings • Nov 17Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$6.59m (up 331% from 3Q 2019). Net loss: US$4.88m (loss narrowed 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 71% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Nov 17Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 163%. Earnings per share (EPS) missed analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 154%, compared to a 365% growth forecast for the Biotechs industry in the US.Major Estimate Revision • Nov 14Analysts update estimatesThe 2020 consensus revenue estimate increased from US$8.33m to US$11.7m. Earning per share (EPS) estimate was further reduced from -US$1.35 to -US$2.11 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target was lowered from US$20.30 to US$20.00. Share price is up 7.4% to US$4.78 over the past week.이익 및 매출 성장 예측NasdaqCM:BIOC - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202521-17N/AN/A112/31/20246-23N/AN/A112/31/20232-22N/AN/A16/30/20231-31-18-18N/A3/31/20237-37-19-19N/A12/31/202226-32-14-13N/A9/30/202241-25-9-7N/A6/30/202257-16-5-4N/A3/31/202263-812N/A12/31/202161-324N/A9/30/2021662-11N/A6/30/202155-2-7-5N/A3/31/202144-7-15-14N/A12/31/202027-18-21-20N/A9/30/202011-25-25-24N/A6/30/20206-26-24-23N/A3/31/20206-28-24-23N/A12/31/20196-25-24-23N/A9/30/20195-26-23-23N/A6/30/20194-27-23-23N/A3/31/20193-25-22-22N/A12/31/20183-25-23-22N/A9/30/20183-25-23-23N/A6/30/20184-24-23-22N/A3/31/20184-24-23-21N/A12/31/20175-22-21-20N/A9/30/20175-20-19-18N/A6/30/20175-19-17-16N/A3/31/20175-18N/A-15N/A12/31/20163-18N/A-16N/A9/30/20162-19N/A-16N/A6/30/20161-19N/A-16N/A3/31/20161-18N/A-16N/A12/31/20151-17N/A-15N/A9/30/20150-16N/A-14N/A6/30/20150-16N/A-14N/A3/31/20150-15N/A-13N/A12/31/20140-16N/A-15N/A9/30/20140-14N/A-13N/A6/30/20140-13N/A-11N/A3/31/20140-12N/A-10N/A12/31/20130-9N/A-6N/A9/30/20130-10N/A-7N/A6/30/20130-10N/A-7N/A3/31/20130-11N/A-8N/A12/31/20120-12N/A-9N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: BIOC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: BIOC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: BIOC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: BIOC 의 수익(연간 67.1%)이 US 시장(연간 11.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: BIOC 의 수익(연간 67.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: BIOC의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/10/15 07:23종가2023/10/13 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biocept, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Raghuram SelvarajuAegis Capital CorporationSally YanchusBrookline Capital MarketsKumaraguru RajaBrookline Capital Markets4명의 분석가 더 보기
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.
Breakeven Date Change • Apr 18No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.
Breakeven Date Change • Feb 14Forecast to breakeven in 2025The 2 analysts covering Biocept expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$5.04m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
Major Estimate Revision • May 19Consensus revenue estimates increase to US$37.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$28.4m to US$37.5m. Forecast losses expected to reduce from -US$1.17 to -US$0.82 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$12.00 unchanged from last update. Share price was steady at US$4.59 over the past week.
Price Target Changed • May 09Price target decreased to US$12.00Down from US$20.30, the current price target is provided by 1 analyst. New target price is 161% above last closing price of US$4.61. Stock is up 12% over the past year.
분석 기사 • Dec 22Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?With the business potentially at an important milestone, we thought we'd take a closer look at Biocept, Inc.'s...
공지 • Oct 26Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite IndexBiocept, Inc. will be removed from NASDAQ Composite Index.
공지 • Oct 21Biocept's Securities To Be Delisted from NasdaqOn October 16, 2023, Biocept, Inc. received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined that the Company’s securities will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, in connection with the filing of a voluntary case under Chapter 7 of Title 11 of the United States Bankruptcy Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 2023. Pursuant to the Delisting Notice, Nasdaq’s decision was based on the following factors: (i) The public interest concerns raised by the filing; (ii) concerns regarding the residual equity interest of the existing listed securities holders; and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, on May 17, 2023, Staff also notified the Company that it failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing pursuant to Listing Rule 5550(b)(1), which deficiency serves as an additional and separate basis for delisting. The Staff letter indicates that the trading of the Company’s common stock and warrants will be suspended at the opening of business on October 25, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to appeal the determination and, therefore, it is expected that its Common Stock will be delisted, which would not affect any actions it may take in bankruptcy. Trading of the Common Stock will be suspended by Nasdaq at the opening of business on October 25, 2023.
공지 • Oct 19Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI IndexBiocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index
공지 • Sep 22Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung CancerBiocept, Inc. announced the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. The FORESEE trial is specifically designed to measure the impact of CNSide on physicians' clinical decisions to generate the data needed to help reach this goal. FORESEE is a two-part prospective clinical trial designed to follow subjects and collect data from each enrollee at four key time points in their treatment, as well as to compare CNSide cell detection in the cerebrospinal fluid to that of conventional cytology. CNSide has notable advantages over current standards of care, such as cytology, clinical evaluation and MRI, which have limited sensitivity and specificity. Biocept expects to have results from the feasibility phase of the FORESEE trial in the first half of 2024 and to then begin enrolling between 40 and 100 subjects in the trial's validation phase. Enrollment is currently open at four clinical sites with two additional sites expected to join the FORESEE trial in The near term.
New Risk • Aug 17New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: US$1.4m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$19m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (327% increase in shares outstanding). Market cap is less than US$10m (US$2.24m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.6m net loss in 3 years). Revenue is less than US$5m (US$1.4m revenue).
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)Second quarter 2023 results: US$3.50 loss per share (improved from US$16.83 loss in 2Q 2022). Net loss: US$3.63m (loss narrowed 62% from 2Q 2022). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.
공지 • Jun 21+ 1 more updateBiocept, Inc. Announces Executive ChangesBiocept, Inc. has named Antonino Morales as President effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer, and Director. Mr. Morales has served as a member of Biocept's Board since July 2021 and was a member of the Audit Committee from August 2021 until his appointment as interim Chief Financial Officer. He has more than 30 years of broad executive leadership experience and has served in executive management or consulting roles with various Fortune 100 companies, including Citibank, Bank of America, Arthur Andersen, Mazda North America and McDonald's. Mr. Morales has also led multiple private equity-backed startup companies. He received a Bachelor of Science in Finance from the University of Southern California and is a licensed CPA.
공지 • May 16Biocept Expects to Receive Non-Compliance Notice Form NasdaqAs reported in Biocept, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on May 10, 2023, the Company's stockholders' equity as of March 31, 2023 was $2.4 million. As a result, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirements set in Nasdaq Stock Market Rule 5550(b) (the Rule"). The Company expects to receive a formal notice (the Notice") from The Nasdaq Stock Market LLC (Nasdaq") on or about May 15, 2023 to formally notify the Company of non-compliance with the Rule. The Company discussed the noncompliance with the Rule with Nasdaq on May 12, 2023. Pursuant to the Notice and Nasdaq rules, the Company will have 45 calendar days after receipt of the Notice to submit a plan to regain compliance with the Rule. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to provide evidence of compliance. There can be no assurance that the Company will be able to regain compliance with the Rule.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.
Breakeven Date Change • Apr 18No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.
분석 기사 • Apr 17Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For GrowthThose holding Biocept, Inc. ( NASDAQ:BIOC ) shares would be relieved that the share price has rebounded 48% in the last...
Breakeven Date Change • Feb 14Forecast to breakeven in 2025The 2 analysts covering Biocept expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$5.04m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$2.16, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 79% over the past three years.
Reported Earnings • Feb 17Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2021 results: US$0.041 loss per share (up from US$0.37 loss in 3Q 2020). Revenue: US$17.5m (up 165% from 3Q 2020). Net loss: US$624.7k (loss narrowed 87% from 3Q 2020). Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 37% compared to a 187% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$3.95, the stock trades at a trailing P/E ratio of 21.5x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 65% over the past three years.
분석 기사 • Nov 23Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True PositionEven though Biocept, Inc. ( NASDAQ:BIOC ) posted strong earnings recently, the stock hasn't reacted in a large way. We...
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$34.9m (up 431% from 3Q 2020). Net income: US$854.1k (up US$5.73m from 3Q 2020). Profit margin: 2.4% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 19Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) EarningsCelebrations may be in order for Biocept, Inc. ( NASDAQ:BIOC ) shareholders, with the covering analyst delivering a...
Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$12.0m (up US$11.1m from 2Q 2020). Net loss: US$1.83m (loss narrowed 72% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
분석 기사 • Jul 03Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time BeingIn the past three years, the share price of Biocept, Inc. ( NASDAQ:BIOC ) has struggled to grow and now shareholders...
Major Estimate Revision • May 19Consensus revenue estimates increase to US$37.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$28.4m to US$37.5m. Forecast losses expected to reduce from -US$1.17 to -US$0.82 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$12.00 unchanged from last update. Share price was steady at US$4.59 over the past week.
Reported Earnings • May 13First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$17.8m (up US$16.3m from 1Q 2020). Net income: US$2.60m (up US$10.9m from 1Q 2020). Profit margin: 15% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Price Target Changed • May 09Price target decreased to US$12.00Down from US$20.30, the current price target is provided by 1 analyst. New target price is 161% above last closing price of US$4.61. Stock is up 12% over the past year.
Reported Earnings • Mar 31Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$27.5m (up 397% from FY 2019). Net loss: US$17.8m (loss narrowed 30% from FY 2019). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 13Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price GainBiocept, Inc. ( NASDAQ:BIOC ) shareholders might be concerned after seeing the share price drop 19% in the last month...
Is New 90 Day High Low • Feb 05New 90-day high: US$6.70The company is up 51% from its price of US$4.45 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
분석 기사 • Jan 26We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, Biocept ( NASDAQ:BIOC ) stock...
Is New 90 Day High Low • Jan 20New 90-day high: US$6.23The company is up 38% from its price of US$4.52 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
분석 기사 • Dec 22Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?With the business potentially at an important milestone, we thought we'd take a closer look at Biocept, Inc.'s...
Reported Earnings • Nov 20Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$6.59m (up 331% from 3Q 2019). Net loss: US$4.88m (loss narrowed 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 71% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Nov 20Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 163%. Earnings per share (EPS) missed analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 154%, compared to a 365% growth forecast for the Biotechs industry in the US.
Reported Earnings • Nov 17Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$6.59m (up 331% from 3Q 2019). Net loss: US$4.88m (loss narrowed 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 71% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Nov 17Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 163%. Earnings per share (EPS) missed analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 154%, compared to a 365% growth forecast for the Biotechs industry in the US.
Major Estimate Revision • Nov 14Analysts update estimatesThe 2020 consensus revenue estimate increased from US$8.33m to US$11.7m. Earning per share (EPS) estimate was further reduced from -US$1.35 to -US$2.11 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target was lowered from US$20.30 to US$20.00. Share price is up 7.4% to US$4.78 over the past week.